Evolving ways that drug therapy is individualized

Clinical Pharmacology and Therapeutics

Volumn 74, Issue 3, 2003, Pages 197-202

  Reidenberg, Marcus M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHENAZONE; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTIMALARIAL AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIPYRONE; FLUOROURACIL; GLYCOSIDE; MERCAPTOPURINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENAZONE; PRIMAQUINE; RESERPINE; SUXAMETHONIUM; TRASTUZUMAB;

AGRANULOCYTOSIS; APNEA; BLOOD DYSCRASIA; BONE MARROW SUPPRESSION; BREAST CANCER; CARDIOVASCULAR DISEASE; DIGESTIVE SYSTEM ULCER; DRUG CHOICE; DRUG PREFERENCE; DRUG SURVEILLANCE PROGRAM; GASTROINTESTINAL HEMORRHAGE; HEMOLYTIC ANEMIA; HUMAN; INDIVIDUALIZATION; MEDICAL DECISION MAKING; MOLECULAR BIOLOGY; NOTE; PHARMACOGENOMICS; PRESCRIPTION; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT PLANNING;

DRUG THERAPY; EPIDEMIOLOGIC METHODS; HUMANS; MOLECULAR BIOLOGY; PHARMACOGENETICS; PHARMACOKINETICS;

EID: 0041831264     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(03)00189-9     Document Type: Note

References (46)

1. Withering W. An account of the foxglove and some of its medical uses. Special edition. Birmingham (AL): Privately printed for the members of the Classics of Medicine Library; 1979.
2. Dameshek W, Colmes A. The effect of drugs in the production of agranulocytosis with particular reference to amidopyrine hypersensitivity. J Clin Invest 1936;15:85-97.
3. Taussig HB. A study of the German outbreak of phocomelia. JAMA 1963;180:1106-14.
4. Schreiner GE, Maher JC. Drugs and the kidney. Ann N Y Acad Sci 1965;123:326-32.
5. Richet G, Fabre J, de Freudenreich J, Podevin R. Drug tolerance of uremic patients. Necessity for a toxicology adapted to visceral insufficiencies. [in French]. Presse Med 1966;74:2339-40.
6. Kunin CM. A guide to the use of antibiotics in patients with renal disease. Ann Intern Med 1967;67:151-8.
7. Reidenberg MM. Renal function and drug action. Philadelphia: Saunders; 1971.
8. Wuth O. Rational bromide therapy. JAMA 1927;287:227-31.
9. Shannon JA. The study of antimalarials and antimalarial activity in the human malarias. Harvey Lectures 1946;41:43-89.
10. Buchthal F, Svensmack O, Schiller PJ. Clinical and electroencephalographic correlation with serum levels of diphenylhydantoin. Arch Neurol 1960;2:624-30.
11. Grahame-Smith DG, Everest MS. Measurement of digoxin in plasma and its use in diagnosis of digoxin intoxication. BMJ 1969;1:826-9.
12. Reidenberg MM, editor: Individualization of drug therapy. Med Clin North Am 1974;58:905-1162.
13. Kalow W. Pharmacogenetics. Philadelphia: Saunders; 1962.
14. LaDu B. Plasma esterase activity and the metabolism of drugs with ester group. Ann N Y Acad Sci 1971;179:684-94.
15. Motulsky AG, Yoshida A, Stamatoyannopoulos G. Variants of glucose-6-phosphate dehydrogenase. Ann N Y Acad Sci 1971;179:636-43.
16. Price-Evans DA. Genetic factors in drug therapy. Cambridge (UK): Cambridge University Press; 1993.
17. Kalow W, Meyer U, Tyndale RF. Interethnic differences in drug response. In: Kalow W, Meyer U, Tyndale RF, editors. Pharmacogenomics. New York: Dekker; 2001. p. 109-34.
18. Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos 2001;29:601-5.
19. Diasio RB, Johnson MR. Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res 1999;5:2672-3.
20. Druker BJ, Lydon NB. Lessons learned from the development of an Ab1 tryosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000;105:3-7.
21. Calvert PM, Frucht H. The genetics of colorectal cancer. Ann Intern Med 2002;137:603-12.
22. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ulrich A. P185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989;9:1165-72.
23. Heaf PJD. Deaths in asthma: a therapeutic misadventure? Br Med Bull 1970;26:245-7.
24. Seppala H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius H, Lager K, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A Streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997;337:441-6.
25. Veterans Administration Cooperative Study Group on Antihypertension Agents. Effects of treatment on morbidity in hypertension. I. JAMA 1967;202:1028-34.
26. Veterans Administration Cooperative Study Group on Antihypertension Agents. Effects of treatment on morbidity in hypertension. II. JAMA 1970;213:1143-52.
27. Fraser HS. Reserpine: a tragic victim of myths, marketing, and fashionable prescribing. Clin Pharmacol Ther 1996;60:368-73.
28. Girard DZ. Intervention times series analysis of pertussis vaccination in England and Wales. Health Policy 2000;54:13-25.
29. Gerson WT, Fine DG, Spielberg SP, Sensenbrenner LL. Anticonvulsant-induced aplastic anemia: increased susceptibility to toxic drug metabolites in vitro. Blood 1983;61:889-93.
30. Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986;105:179-84.
31. Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991;49:13-7.
32. Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1988;105:179-84.
33. Spielberg SP. Pharmacogenetics and blood dyscrasias. Eur J Haematol Suppl 1996;60:93-7.
34. Hedenmalm K, Spigset O. Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Eur J Clin Pharmacol 2002;58:265-74.
35. Kaufman DW, Kelly JP, Levy M, Shapiro S. The drug etiology of agranulocytosis and aplastic anemia. New York: Oxford University Press; 1991.
36. Edwards JE, McQuay HJ. Dipyrone and agranulocytosis: what is the risk? Lancet 2002;360:1438.
37. Schönhöfer P, Offerhaus L, Herxheimer A. Dipyrone and agranulocytosis: what is the risk? [letter]. Lancet 2003;361:968-9.
38. Ehsanullah RS, Page MC, Tildesley G, Wood JR. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ 1988;297:1017-21.
39. Robinson MG, Griffin JW Jr, Bowers J, Kogan FJ, Kogut DG, Lanza FL, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci 1989;34:424-8.
40. Graham DY, White RH, Moreland LW, Schubert TT, Katz R, Jaszewski R, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med 1993;119:257-62.
41. Laporte JR, Carne X, Vidal X, Moreno V, Juan J. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Lancet 1991;37:85-9.
42. Rodriguez LAG, Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001;12:570-6.
43. Hernandez-Diaz S, Rodrigues LAG. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation. Arch Intern Med 2000;160:2093-9.
44. Biour M, Blanquart A, Moore N, Grange JD, Amiot X, Levy VG, et al. Incidence of NSAID-related, severe gastrointestinal bleeding [letter]. Lancet 1987;2:340-1.
45. Carson JL, Strom BL, Soper KA, West SL, Morse ML. The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Arch Intern Med 1987;146:85-8.
46. Andrade SE, Martinez C, Walker AM. Comparative safety evaluation of non-narcotic analgesics. J Clin Epidemiol 1998;51:1357-65.